피부사상균성 조진균증 치료제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2031년) - 치료 유형별, 적응증별, 성별, 연령대별, 최종사용자별, 지역별
Dermatophytic Onychomycosis Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:
상품코드
:
1423795
리서치사
:
Fairfield Market Research
발행일
:
2024년 01월
페이지 정보
:
영문 336 Pages
샘플 요청 목록에 추가
세계 피부사상균성 조진균증 치료제 시장 규모는 2024년부터 2031년까지 큰 폭으로 성장하여 2031년 말까지 103억 달러에 달할 것으로 예상됩니다.
2021년에는 피부사상균성 조진균증 치료에 사용되는 약물이 전체 시장 점유율의 거의 4분의 3을 차지하며 43억 6,000만 달러로 평가됐습니다. 이러한 우위는 이 흔한 손발톱 질환을 치료하기 위한 의약품 개입에 크게 의존하고 있음을 강조합니다.
피부사상균성 조진균증은 전 세계 인구의 약 10%가 앓고 있으며, 특히 60세 이상 노년층의 유병률이 높습니다. 그 요인으로는 말초면역질환, 혈관질환, 당뇨병 등을 들 수 있으며, 당뇨병 환자의 위험도가 유의하게 높은 것으로 알려져 있습니다. 또한, 지역별로 유병률이 다른데, 열대 아시아 국가에서는 4-5%인 반면, 유럽 국가에서는 최대 17%에 달합니다.
진단 및 항진균제 검사에 대한 수요 증가로 인해 손발톱 백선 치료제 제조업체는 예측 기간 동안 큰 비지니스 기회를 얻을 수 있을 것으로 보입니다. 의료진과 환자들 사이에서 진균성 손발톱 감염에 대한 인식이 높아지면서 진행 중인 임상 연구 및 의약품 파이프라인의 개발과 함께 시장 성장을 더욱 촉진할 것으로 예상됩니다.
이 보고서는 세계 피부사상균성 조진균증 치료제 시장을 조사했으며, 시장 개요와 함께 치료 유형별, 적응증별, 성별, 연령대별, 최종사용자별, 지역별 동향, 시장 진입 기업의 경쟁 동향 등을 조사하여 전해드립니다.
목차 제1장 주요 요약
제2장 시장 개요
시장 정의와 세분화
시장 역학
밸류체인 분석
Porter's Five Forces 분석
COVID-19의 영향 분석
우크라이나와 러시아 분쟁의 영향
경제 개요
PESTLE 분석
제3장 세계의 피부사상균성 조진균증 치료제 시장 전망, 2018-2031년
세계의 피부사상균성 조진균증 치료제 시장 전망, 치료별, 금액(10억 달러), 2018-2031년
세계의 피부사상균성 조진균증 치료제 시장 전망, 적응증별, 금액(10억 달러), 2018-2031년
세계의 피부사상균성 조진균증 치료제 시장 전망, 성별, 금액(10억 달러), 2018-2031년
세계의 피부사상균성 조진균증 치료제 시장 전망, 연령층별, 금액(10억 달러), 2018-2031년
세계의 피부사상균성 조진균증 치료제 시장 전망, 유통 채널별, 금액(10억 달러), 2018-2031년
세계의 피부사상균성 조진균증 치료제 시장 전망, 지역별, 금액(10억 달러), 2018-2031년
제4장 북미의 피부사상균성 조진균증 치료제 시장 전망, 2018-2031년
제5장 유럽의 피부사상균성 조진균증 치료제 시장 전망, 2018-2031년
제6장 아시아태평양의 피부사상균성 조진균증 치료제 시장 전망, 2018-2031년
제7장 라틴아메리카의 피부사상균성 조진균증 치료제 시장 전망, 2018-2031년
제8장 중동 및 아프리카의 피부사상균성 조진균증 치료제 시장 전망, 2018-2031년
제9장 경쟁 상황
제품과 적응증 히트맵
기업의 시장 점유율 분석, 2022년
경쟁 대시보드
기업 개요
Bausch Health
Galderma S.A.
Novartis AG
Pfizer, Inc.
Moberg Pharma AB
Bayer AG
Dr. Reddy's Laboratories Ltd.
Cipla Ltd.
Medimetriks Pharmaceuticals, Inc.
Sanofi S.A.
GlaxoSmithKline Plc.
Teva Pharmaceutical industries Ltd.
제10장 부록
ksm
영문 목차
The global dermatophytic onychomycosis therapeutics market is poised for substantial growth from 2024 to 2031. According to the latest industry analysis by Fairfield Market Research, is anticipated to reach an impressive valuation of US$ 10.30 billion by the end of 2031.
Market Dominance of Drug Therapies
In 2021, drugs used for treating dermatophytic onychomycosis accounted for nearly three-fourths of the overall market share, valued at US$ 4.36 billion. This dominance underscores the significant reliance on pharmaceutical interventions to address this common nail disorder.
Global Prevalence and Contributing Factors
Dermatophytic onychomycosis affects approximately 10% of the global population, with higher prevalence rates among older adults, particularly those above 60 years of age. Contributing factors include peripheral immunologic disorders, vascular disease, and diabetes mellitus, with diabetic patients facing a significantly higher risk. Moreover, prevalence rates vary across regions, ranging from 4%-5% in tropical Asian countries to up to 17% in European countries.
Future Opportunities and Market Dynamics
The forecast period presents lucrative opportunities for dermatophytic onychomycosis therapeutic drug manufacturers, driven by rising demand for diagnosis and antifungal testing. Increased awareness of fungal nail infections among healthcare professionals and patients, coupled with ongoing clinical studies and developments in drug pipelines, are expected to further propel market growth.
Challenges and Constraints
Despite the promising outlook, challenges such as low elasticity of demand and the non-life-threatening nature of the condition restrain market growth to some extent. Treatment failures, recurrent infections, and competition from alternative therapies pose additional challenges for stakeholders in the dermatophytic onychomycosis therapeutics market.
Regional Insights
In the United States, frequent FDA approvals and the high prevalence of chronic diseases such as diabetes contribute to the country's leading market share. Germany benefits from the presence of major industry players, while China's market growth is fueled by collaborative research efforts and strategic expansions in medical infrastructure.
Key Market Drivers and Competitive Landscape
The drugs segment remains the primary driver of market growth, with distal subungual onychomycosis emerging as the most prevalent indication. Key manufacturers are focused on expanding their product portfolios, obtaining regulatory approvals, and forging strategic partnerships to enhance market presence and revenue streams.
Key Segments Covered in Dermatophytic Onychomycosis Therapeutics Industry Survey:
Dermatophytic Onychomycosis Therapeutics Market by Treatment Type:
Dermatophytic Onychomycosis Therapeutic Drugs
Rx
OTC
Rx
OTC
Dermatophytic Onychomycosis Therapeutic Lasers
C02 Ablative Lasers
Nd:YAG Lasers
Dual-wave length near-infrared Lasers
Photodynamic Therapy
Dermatophytic Onychomycosis Therapeutics Market by Indication:
Distal Subungual Onychomycosis
White Superficial Onychomycosis
Proximal Subungual Onychomycosis
Candidal Onychomycosis
Total Dystrophic Onychomycosis
Dermatophytic Onychomycosis Therapeutics Market by Gender:
Dermatophytic Onychomycosis Therapeutics Market by Age Group:
0-18 Years
18-39 Years
40-64 Years
65 Years and Above
Dermatophytic Onychomycosis Therapeutics Market by End User:
Institutional Sales
Hospitals
Dermatology Clinics
Retail Sales
Retail Pharmacies
Drug Stores
Mail Order Pharmacies & Online Sales
Dermatophytic Onychomycosis Therapeutics Market by Region:
North America Dermatophytic Onychomycosis Therapeutics Market
Latin America Dermatophytic Onychomycosis Therapeutics Market
Europe Dermatophytic Onychomycosis Therapeutics Market
South Asia Dermatophytic Onychomycosis Therapeutics Market
East Asia Dermatophytic Onychomycosis Therapeutics Market
Oceania Dermatophytic Onychomycosis Therapeutics Market
Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market
Table of Contents 1. Executive Summary
1.1. Global Dermatophytic Onychomycosis Therapeutics Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Dermatophytic Onychomycosis Therapeutics Market Outlook, 2018 - 2031
3.1. Global Dermatophytic Onychomycosis Therapeutics Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Dermatophytic Onychomycosis Therapeutic Drugs
3.1.1.1.1. Oral
3.1.1.1.1.1. Rx
3.1.1.1.1.2. OTC
3.1.1.1.2. Topical
3.1.1.1.2.1. Rx
3.1.1.1.2.2. OTC
3.1.1.2. Dermatophytic Onychomycosis Therapeutic Lasers
3.1.1.2.1. C02 Ablative Lasers
3.1.1.2.2. Nd:YAG Lasers
3.1.1.2.3. Dual-wavelength near-infrared Lasers
3.1.1.3. Photodynamic Therapy
3.2. Global Dermatophytic Onychomycosis Therapeutics Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Distal Subungual Onychomycosis
3.2.1.2. White Superficial Onychomycosis
3.2.1.3. Proximal Subungual Onychomycosis
3.2.1.4. Candidal Onychomycosis
3.2.1.5. Total Dystrophic Onychomycosis
3.3. Global Dermatophytic Onychomycosis Therapeutics Market Outlook, by Gender, Value (US$ Bn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Male
3.3.1.2. Female
3.4. Global Dermatophytic Onychomycosis Therapeutics Market Outlook, by Age Group, Value (US$ Bn), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. 0-18 Years
3.4.1.2. 18-39 Years
3.4.1.3. 40-64 Years
3.4.1.4. 65 Years and Above
3.5. Global Dermatophytic Onychomycosis Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
3.5.1. Key Highlights
3.5.1.1. Institutional Sales
3.5.1.1.1. Hospitals
3.5.1.1.2. Dermatology Clinics
3.5.1.2. Retail Sales
3.5.1.2.1. Retail Pharmacies
3.5.1.2.2. Drug Stores
3.5.1.2.3. Mail Order Pharmacies & Online Sales
3.6. Global Dermatophytic Onychomycosis Therapeutics Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
3.6.1. Key Highlights
3.6.1.1. North America
3.6.1.2. Europe
3.6.1.3. Asia Pacific
3.6.1.4. Latin America
3.6.1.5. Middle East & Africa
4. North America Dermatophytic Onychomycosis Therapeutics Market Outlook, 2018 - 2031
4.1. North America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Dermatophytic Onychomycosis Therapeutic Drugs
4.1.1.1.1. Oral
4.1.1.1.1.1. Rx
4.1.1.1.1.2. OTC
4.1.1.1.2. Topical
4.1.1.1.2.1. Rx
4.1.1.1.2.2. OTC
4.1.1.2. Dermatophytic Onychomycosis Therapeutic Lasers
4.1.1.2.1. C02 Ablative Lasers
4.1.1.2.2. Nd:YAG Lasers
4.1.1.3. Dual-wavelength near-infrared Lasers
4.2. North America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Distal Subungual Onychomycosis
4.2.1.2. White Superficial Onychomycosis
4.2.1.3. Proximal Subungual Onychomycosis
4.2.1.4. Candidal Onychomycosis
4.2.1.5. Total Dystrophic Onychomycosis
4.3. North America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Gender, Value (US$ Bn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Male
4.3.1.2. Female
4.4. North America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Age Group, Value (US$ Bn), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. 0-18 Years
4.4.1.2. 18-39 Years
4.4.1.3. 40-64 Years
4.4.1.4. 65 Years and Above
4.5. North America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.5.1. Key Highlights
4.5.1.1. Institutional Sales
4.5.1.1.1. Hospitals
4.5.1.1.2. Dermatology Clinics
4.5.1.2. Retail Sales
4.5.1.2.1. Retail Pharmacies
4.5.1.2.2. Drug Stores
4.5.1.2.3. Mail Order Pharmacies & Online Sales
4.5.2. BPS Analysis/Market Attractiveness Analysis
4.6. North America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
4.6.1. Key Highlights
4.6.1.1. U.S. Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
4.6.1.2. U.S. Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
4.6.1.3. U.S. Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
4.6.1.4. U.S. Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
4.6.1.5. U.S. Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.6.1.6. Canada Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
4.6.1.7. Canada Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
4.6.1.8. Canada Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
4.6.1.9. Canada Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
4.6.1.10. Canada Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.6.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Dermatophytic Onychomycosis Therapeutics Market Outlook, 2018 - 2031
5.1. Europe Dermatophytic Onychomycosis Therapeutics Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Dermatophytic Onychomycosis Therapeutic Drugs
5.1.1.1.1. Oral
5.1.1.1.1.1. Rx
5.1.1.1.1.2. OTC
5.1.1.1.2. Topical
5.1.1.1.2.1. Rx
5.1.1.1.2.2. OTC
5.1.1.2. Dermatophytic Onychomycosis Therapeutic Lasers
5.1.1.2.1. C02 Ablative Lasers
5.1.1.2.2. Nd:YAG Lasers
5.1.1.3. Dual-wavelength near-infrared Lasers
5.2. Europe Dermatophytic Onychomycosis Therapeutics Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Distal Subungual Onychomycosis
5.2.1.2. White Superficial Onychomycosis
5.2.1.3. Proximal Subungual Onychomycosis
5.2.1.4. Candidal Onychomycosis
5.2.1.5. Total Dystrophic Onychomycosis
5.3. Europe Dermatophytic Onychomycosis Therapeutics Market Outlook, by Gender, Value (US$ Bn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Male
5.3.1.2. Female
5.4. Europe Dermatophytic Onychomycosis Therapeutics Market Outlook, by Age Group, Value (US$ Bn), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. 0-18 Years
5.4.1.2. 18-39 Years
5.4.1.3. 40-64 Years
5.4.1.4. 65 Years and Above
5.5. Europe Dermatophytic Onychomycosis Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.5.1. Key Highlights
5.5.1.1. Institutional Sales
5.5.1.1.1. Hospitals
5.5.1.1.2. Dermatology Clinics
5.5.1.2. Retail Sales
5.5.1.2.1. Retail Pharmacies
5.5.1.2.2. Drug Stores
5.5.1.2.3. Mail Order Pharmacies & Online Sales
5.5.2. BPS Analysis/Market Attractiveness Analysis
5.6. Europe Dermatophytic Onychomycosis Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
5.6.1. Key Highlights
5.6.1.1. Germany Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
5.6.1.2. Germany Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
5.6.1.3. Germany Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
5.6.1.4. Germany Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
5.6.1.5. Germany Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.6.1.6. U.K. Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
5.6.1.7. U.K. Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
5.6.1.8. U.K. Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
5.6.1.9. U.K. Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
5.6.1.10. U.K. Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.6.1.11. France Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
5.6.1.12. France Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
5.6.1.13. France Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
5.6.1.14. France Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
5.6.1.15. France Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.6.1.16. Italy Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
5.6.1.17. Italy Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
5.6.1.18. Italy Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
5.6.1.19. Italy Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
5.6.1.20. Italy Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.6.1.21. Turkey Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
5.6.1.22. Turkey Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
5.6.1.23. Turkey Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
5.6.1.24. Turkey Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
5.6.1.25. Turkey Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.6.1.26. Russia Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
5.6.1.27. Russia Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
5.6.1.28. Russia Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
5.6.1.29. Russia Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
5.6.1.30. Russia Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.6.1.31. Rest of Europe Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
5.6.1.32. Rest of Europe Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
5.6.1.33. Rest of Europe Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
5.6.1.34. Rest of Europe Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
5.6.1.35. Rest of Europe Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.6.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Dermatophytic Onychomycosis Therapeutics Market Outlook, 2018 - 2031
6.1. Asia Pacific Dermatophytic Onychomycosis Therapeutics Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
6.1.1.1. Key Dermatophytic Onychomycosis Therapeutic Drugs
6.1.1.1.1. Oral
6.1.1.1.1.1. Rx
6.1.1.1.1.2. OTC
6.1.1.1.2. Topical
6.1.1.1.2.1. Rx
6.1.1.1.2.2. OTC
6.1.1.2. Dermatophytic Onychomycosis Therapeutic Lasers
6.1.1.2.1. C02 Ablative Lasers
6.1.1.2.2. Nd:YAG Lasers
6.1.2. Dual-wavelength near-infrared Lasers
6.2. Asia Pacific Dermatophytic Onychomycosis Therapeutics Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Distal Subungual Onychomycosis
6.2.1.2. White Superficial Onychomycosis
6.2.1.3. Proximal Subungual Onychomycosis
6.2.1.4. Candidal Onychomycosis
6.2.1.5. Total Dystrophic Onychomycosis
6.3. Asia Pacific Dermatophytic Onychomycosis Therapeutics Market Outlook, by Gender, Value (US$ Bn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Male
6.3.1.2. Female
6.4. Asia Pacific Dermatophytic Onychomycosis Therapeutics Market Outlook, by Age Group, Value (US$ Bn), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. 0-18 Years
6.4.1.2. 18-39 Years
6.4.1.3. 40-64 Years
6.4.1.4. 65 Years and Above
6.5. Asia Pacific Dermatophytic Onychomycosis Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.5.1. Key Highlights
6.5.1.1. Institutional Sales
6.5.1.1.1. Hospitals
6.5.1.1.2. Dermatology Clinics
6.5.1.2. Retail Sales
6.5.1.2.1. Retail Pharmacies
6.5.1.2.2. Drug Stores
6.5.1.2.3. Mail Order Pharmacies & Online Sales
6.5.2. BPS Analysis/Market Attractiveness Analysis
6.6. Asia Pacific Dermatophytic Onychomycosis Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
6.6.1. Key Highlights
6.6.1.1. China Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
6.6.1.2. China Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
6.6.1.3. China Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
6.6.1.4. China Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
6.6.1.5. China Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.6.1.6. Japan Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
6.6.1.7. Japan Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
6.6.1.8. Japan Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
6.6.1.9. Japan Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
6.6.1.10. Japan Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.6.1.11. South Korea Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
6.6.1.12. South Korea Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
6.6.1.13. South Korea Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
6.6.1.14. South Korea Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
6.6.1.15. South Korea Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.6.1.16. India Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
6.6.1.17. India Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
6.6.1.18. India Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
6.6.1.19. India Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
6.6.1.20. India Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.6.1.21. Southeast Asia Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
6.6.1.22. Southeast Asia Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
6.6.1.23. Southeast Asia Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
6.6.1.24. Southeast Asia Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
6.6.1.25. Southeast Asia Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.6.1.26. Rest of Asia Pacific Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
6.6.1.27. Rest of Asia Pacific Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
6.6.1.28. Rest of Asia Pacific Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
6.6.1.29. Rest of Asia Pacific Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
6.6.1.30. Rest of Asia Pacific Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.6.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Dermatophytic Onychomycosis Therapeutics Market Outlook, 2018 - 2031
7.1. Latin America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Dermatophytic Onychomycosis Therapeutic Drugs
7.1.1.1.1. Oral
7.1.1.1.1.1. Rx
7.1.1.1.1.2. OTC
7.1.1.1.2. Topical
7.1.1.1.2.1. Rx
7.1.1.1.2.2. OTC
7.1.1.2. Dermatophytic Onychomycosis Therapeutic Lasers
7.1.1.2.1. C02 Ablative Lasers
7.1.1.2.2. Nd:YAG Lasers
7.1.1.3. Dual-wavelength near-infrared Lasers
7.2. Latin America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
7.2.1.1. Distal Subungual Onychomycosis
7.2.1.2. White Superficial Onychomycosis
7.2.1.3. Proximal Subungual Onychomycosis
7.2.1.4. Candidal Onychomycosis
7.2.1.5. Total Dystrophic Onychomycosis
7.3. Latin America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Gender, Value (US$ Bn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Male
7.3.1.2. Female
7.4. Latin America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Age Group, Value (US$ Bn), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. 0-18 Years
7.4.1.2. 18-39 Years
7.4.1.3. 40-64 Years
7.4.1.4. 65 Years and Above
7.5. Latin America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.5.1. Key Highlights
7.5.1.1. Institutional Sales
7.5.1.1.1. Hospitals
7.5.1.1.2. Dermatology Clinics
7.5.1.2. Retail Sales
7.5.1.2.1. Retail Pharmacies
7.5.1.2.2. Drug Stores
7.5.1.2.3. Mail Order Pharmacies & Online Sales
7.5.2. BPS Analysis/Market Attractiveness Analysis
7.6. Latin America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
7.6.1. Key Highlights
7.6.1.1. Brazil Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
7.6.1.2. Brazil Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
7.6.1.3. Brazil Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
7.6.1.4. Brazil Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
7.6.1.5. Brazil Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.6.1.6. Mexico Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
7.6.1.7. Mexico Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
7.6.1.8. Mexico Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
7.6.1.9. Mexico Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
7.6.1.10. Mexico Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.6.1.11. Argentina Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
7.6.1.12. Argentina Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
7.6.1.13. Argentina Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
7.6.1.14. Argentina Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
7.6.1.15. Argentina Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.6.1.16. Rest of Latin America Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
7.6.1.17. Rest of Latin America Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
7.6.1.18. Rest of Latin America Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
7.6.1.19. Rest of Latin America Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
7.6.1.20. Rest of Latin America Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.6.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market Outlook, 2018 - 2031
8.1. Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Dermatophytic Onychomycosis Therapeutic Drugs
8.1.1.1.1. Oral
8.1.1.1.1.1. Rx
8.1.1.1.1.2. OTC
8.1.1.1.2. Topical
8.1.1.1.2.1. Rx
8.1.1.1.2.2. OTC
8.1.1.2. Dermatophytic Onychomycosis Therapeutic Lasers
8.1.1.2.1. C02 Ablative Lasers
8.1.1.2.2. Nd:YAG Lasers
8.1.1.3. Dual-wavelength near-infrared Lasers
8.2. Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Distal Subungual Onychomycosis
8.2.1.2. White Superficial Onychomycosis
8.2.1.3. Proximal Subungual Onychomycosis
8.2.1.4. Candidal Onychomycosis
8.2.1.5. Total Dystrophic Onychomycosis
8.3. Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market Outlook, by Gender, Value (US$ Bn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Male
8.3.1.2. Female
8.4. Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market Outlook, by Age Group, Value (US$ Bn), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. 0-18 Years
8.4.1.2. 18-39 Years
8.4.1.3. 40-64 Years
8.4.1.4. 65 Years and Above
8.5. Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.5.1. Key Highlights
8.5.1.1. Institutional Sales
8.5.1.1.1. Hospitals
8.5.1.1.2. Dermatology Clinics
8.5.1.2. Retail Sales
8.5.1.2.1. Retail Pharmacies
8.5.1.2.2. Drug Stores
8.5.1.2.3. Mail Order Pharmacies & Online Sales
8.5.2. BPS Analysis/Market Attractiveness Analysis
8.6. Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
8.6.1. Key Highlights
8.6.1.1. GCC Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
8.6.1.2. GCC Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
8.6.1.3. GCC Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
8.6.1.4. GCC Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
8.6.1.5. GCC Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.6.1.6. South Africa Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
8.6.1.7. South Africa Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
8.6.1.8. South Africa Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
8.6.1.9. South Africa Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
8.6.1.10. South Africa Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.6.1.11. Egypt Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
8.6.1.12. Egypt Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
8.6.1.13. Egypt Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
8.6.1.14. Egypt Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
8.6.1.15. Egypt Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.6.1.16. Nigeria Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
8.6.1.17. Nigeria Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
8.6.1.18. Nigeria Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
8.6.1.19. Nigeria Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
8.6.1.20. Nigeria Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.6.1.21. Rest of Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
8.6.1.22. Rest of Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
8.6.1.23. Rest of Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
8.6.1.24. Rest of Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
8.6.1.25. Rest of Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.6.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Product vs Indication Heatmap
9.2. Company Market Share Analysis, 2022
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Bausch Health
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Galderma S.A.
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. Novartis AG
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. Pfizer, Inc.
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Moberg Pharma AB
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Bayer AG
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. Dr. Reddy's Laboratories Ltd.
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
9.4.8. Cipla Ltd.
9.4.8.1. Company Overview
9.4.8.2. Product Portfolio
9.4.8.3. Financial Overview
9.4.8.4. Business Strategies and Development
9.4.9. Medimetriks Pharmaceuticals, Inc.
9.4.9.1. Company Overview
9.4.9.2. Product Portfolio
9.4.9.3. Financial Overview
9.4.9.4. Business Strategies and Development
9.4.10. Sanofi S.A.
9.4.10.1. Company Overview
9.4.10.2. Product Portfolio
9.4.10.3. Financial Overview
9.4.10.4. Business Strategies and Development
9.4.11. GlaxoSmithKline Plc.
9.4.11.1. Company Overview
9.4.11.2. Product Portfolio
9.4.11.3. Financial Overview
9.4.11.4. Business Strategies and Development
9.4.12. Teva Pharmaceutical industries Ltd.
9.4.12.1. Company Overview
9.4.12.2. Product Portfolio
9.4.12.3. Financial Overview
9.4.12.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations
관련자료
